J&J to acquire Rhinocort Aqua outside the US
Παρασκευή 14 Οκτ 2016
Johnson & Johnson is set to acquire the rights to AstraZeneca's Rhinocort Aqua nasal spray outside the US in a deal worth US$330 million.
The active ingredient of Rhinocort Aqua – budesonide – is generally a prescription medicine outside the US, but is available without a prescription in some countries including Australia, China, New Zealand, and Singapore.

In the US, Johnson & Johnson acquired the OTC rights to Rhinocort Aqua from AstraZeneca in 2014. The OTC version of the medicine – Rhinocort Allergy Spray – was launched in February 2016, following the switch of the active ingredient from prescription-to-OTC status in 2015.

Rhinocort Allergy Spray provides 32µg budesonide per spray. The company points out that the nasal spray is "scent-free and alcohol-free", and offers "24 hour non drowsy relief" from nasal congestion, runny nose, itchy nose and sneezing.

The OTC version of Rhinocort Aqua joined Johnson & Johnson's existing portfolio of OTC allergy remedies in the US, which includes the Zyrtec range based on the antihistamine cetirizine and the Benadryl Allergy line containing the antihistamine diphenhydramine.

From the makers of Zyrtec

Marketing materials for Rhinocort Allergy Spray point out that the medicine is "From the makers of Zyrtec".

Rhinocort Allergy Spray was the third nasal corticosteroid spray to be switched from prescription-to-OTC status in the US. Sanofi launched Nasacort Allergy 24HR (triamcinolone acetonide) in February 2014, while GlaxoSmithKline introduced Flonase Allergy Relief (fluticasone propionate) in February 2015.

AstraZeneca said the deal outside the US should be completed in the fourth quarter of 2016. The transaction will not include the transfer of any employees or facilities.

Πηγή:  OTC Tool Box

Σχετικά Άρθρα

Κανένα σχόλιο... κάνετε ένα δικό σας σχόλιο

Κάνετε Login για να σχολιάσετε το άρθρο